After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $11.74 and fluctuated between $12.36 as its day high and $11.51 as its day low. The current market capitalization of Alx Oncology Holdings Inc is $588.76M. A total of 0.53 million shares were traded on the day, compared to an average of 381.06K shares.
In the most recent transaction, Lettmann Jason bought 4,400 shares of ALXO for 11.31 per share on Mar 14 ’24. After the transaction, the CHIEF EXECUTIVE OFFICER now owns 171,620 company shares. In a previous transaction on Jan 04 ’24, Pinto Shelly sold 2,717 shares at 13.60 per share. ALXO shares that SVP, Finance and CAO owns now total 78,591.
Among the insiders who sold shares, Pons Jaume disposed of 7,179 shares on Dec 29 ’23 at a per-share price of $15.04. This resulted in the President & CSO holding 618,359 shares of ALXO after the transaction. In another insider transaction, Randolph Sophia sold 3,128 shares at $15.04 per share on Dec 29 ’23. Company shares held by the Chief Medical Officer now total 312,349.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, ALXO has a high of $17.42 and a low of $3.94.
As of this writing, ALXO has an earnings estimate of -$0.84 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.64 per share and a lower estimate of -$0.99. The company reported an EPS of -$1.24 in the last quarter, which was -42.50% lower than expectations of -$0.87.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ALXO’s latest balance sheet shows that the firm has $363.67M in Cash & Short Term Investments as of fiscal 2021. There were $742.00k in debt and $15.29M in liabilities at the time. Its Book Value Per Share was $3.80, while its Total Shareholder’s Equity was $363.05M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALXO is Buy with a score of 4.71.
